Gemina Laboratories Strategic Update

Gemina Laboratories Ltd (CSE:GLAB) has announced significant progress in H1 2024, including key licensing deals and new revenue streams. The company signed its first license deal with a global diagnostics company in April, validating its technology after extensive evaluation. Additionally, four other diagnostic companies have signed Non-Disclosure Agreements with Gemina.

Gemina issued its first commercial invoice in June 2024, anticipating maiden revenues in H2 and ramping up in 2025. The company’s R&D team has developed 34 inventions, notably pioneering the use of cellulose for lateral flow tests.

Gemina is exploring markets beyond point-of-care diagnostics, estimating a $7B addressable market. Plans to open a new GMP protein production facility in Vancouver by August are on track.

The company has also commenced trading on the OTCQB Market in the US, expanding its public market exposure.